Free Access
Med Sci (Paris)
Volume 20, Number 11, Novembre 2004
Page(s) 999 - 1003
Section M/S revues
Published online 15 November 2004
  1. Silverstein AM. History of immunology. In : Paul WE, ed. Fundamental immunology. New York : Raven Press, 1984 : 23–40. [Google Scholar]
  2. Casadevall A, Scharff MD. Return to the past : the case for antibody-based therapies in infectious diseases. Clin Infect Dis 1995; 21 : 150–61. [Google Scholar]
  3. Lister PD. Emerging resistance problems among respiratory tract pathogens. Am J Manag Care 2000; 6 : S409–18. [Google Scholar]
  4. Busse PJ, Razvi S, Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol 2002; 109 : 1001–4. [Google Scholar]
  5. Hammarström L, Gardulf A, Hammarström V, et al. Systemic and topical immunoglobulin treatment in immunocompromised patients. Immunol Rev 1994; 139 : 43–70. [Google Scholar]
  6. Enarson DA, Chretien J. Epidemiology of respiratory infectious diseases. Curr Opin Pulm Med 1999; 5 : 128–35. [Google Scholar]
  7. Reynolds HY. Normal and defective respiratory host defenses. In : Pennington JE, ed. Respiratory infections. New York : Raven Press, 1994 : 1–33. [Google Scholar]
  8. Lamari F, Karamanos NK, Papadopoulou-Alataki E, et al. Monitoring of two intravenous immunoglobulin. Preparations for immunoglobulin G subclasses and specific antibodies to bacterial surface antigens and relation with their levels in treated immunodeficient patients. J Pharm Biomed Anal 2000; 22 : 1029–36. [Google Scholar]
  9. Groothuis JR, Simoes EA, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The respiratory syncytial virus immune globulin study group. N Engl J Med 1993; 329 : 1524–30. [Google Scholar]
  10. Baker JC, Melish ME, Hall RT, et al. Intravenous immune globulin for the prevention of nosocomial infection in low-birth-weight neonates. The multicenter group for the study of immune globulin in neonates. N Engl J Med 1992; 327 : 213–9. [Google Scholar]
  11. Fanaroff AA, Korones SB, Wright LL, et al. A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. National institute of child health and human development neonatal research network. N Engl J Med 1994; 330 : 1107–13. [Google Scholar]
  12. Spector SA, Gelber RD, McGrath N, et al. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS clinical trials group. N Engl J Med 1994; 331 : 1181–7. [Google Scholar]
  13. Douzinas EE, Pitaridis MT, Louris G, et al. Prevention of infection in multiple trauma patients by high dose intravenous immunoglobulins. Crit Care Med 2000; 28 : 8–15. [Google Scholar]
  14. Conti DJ, Freed BM, Gruber SA, Lempert N. Prophylaxis of primary cytomegalovirus disease in renal transplant recipients. A trial of ganciclovir vs immunoglobulin. Arch Surg 1994; 129 : 443–7. [Google Scholar]
  15. Granström M, Olinder-Nielsen AM, Holmblad P, et al. Specific immunoglobulin for treatment of whooping cough. Lancet 1991; 338 : 1230–3. [Google Scholar]
  16. De Hennezel L, Ramisse F, Binder P, et al. Effective combination therapy for invasive pneumococcal pneumonia with ampicillin and intravenous immunoglobulins in a mouse model. Antimicrob Agents Chemother 2001; 45 : 316–8. [Google Scholar]
  17. Weltzin R, Monath TP. Intranasal antibody prophylaxis for protection against viral disease. Clin Microbiol Rev 1999; 12 : 383–93. [Google Scholar]
  18. Zeitlin L, Cone RA, Whaley KJ. Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases. Emerg Infect Dis 1999; 5 : 54–64. [Google Scholar]
  19. Ma JK, Hunjan M, Smith R, et al. An investigation into the mechanism of protection by local passive immunization with monoclonal antibodies against Streptococcus mutans. Infect Immun 1990; 58 : 3407–14. [Google Scholar]
  20. Ramisse F, Deramoudt FX, Szatanik M, et al. Effective prophylaxis of influenza A virus pneumonia in mice by topical passive immunotherapy with polyvalent human immunoglobulins or F(ab’)2 fragments. Clin Exp Immunol 1998; 111 : 583–7. [Google Scholar]
  21. Mazanec MB, Kaetzel CS, Lamm ME, et al. Intracellular neutralization of virus by immunoglobulin A antibodies. Proc Natl Acad Sci USA 1992; 89 : 6901–5. [Google Scholar]
  22. Lombry C, Edwards DA, Preat V, Vanbever R. Alveolar macrophages are a primary barrier to pulmonary absorption of macromolecules. Am J Physiol Lung Cell Mol Physiol 2004; 286 : L1002–8. [Google Scholar]
  23. Ramisse F, Szatanik M, Binder P, Alonso JM. Passive local immunotherapy of experimental staphylococcal pneumonia with human intravenous immunoglobulin. J Infect Dis 1993; 168 : 1030–3. [Google Scholar]
  24. Ramisse F, Binder P, Szatanik M, Alonso JM. Passive and active immunotherapy of experimental pneumococcal pneumonia by polyvalent human immunoglobulin or F(ab’)2 fragments administered intranasally. J Infect Dis 1996; 173 : 1123–8. [Google Scholar]
  25. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. Ann Rev Immunol 1994; 12 : 433–55. [Google Scholar]
  26. Breedveld FC. Therapeutic monoclonal antibodies. Lancet 2000; 355 : 735–40. [Google Scholar]
  27. Weltzin R, Traina-Dorge V, Soike K, et al. Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection. J Infect Dis 1996; 174 : 256–61. [Google Scholar]
  28. Johnson S, Griego SD, Pfarr DS, et al. A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies : MEDI-493 and RSHZ19. J Infect Dis 1999; 180 : 35–40. [Google Scholar]
  29. Gavilondo JV, Larrick JW. Antibody engineering at the millenium. Biotechniques 2000; 29 : 128–45. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.